Paradigm Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.31%

Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Paradigm Biopharmaceuticals Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$71.83K
≈ $50.82K USD Cash + Short-term Investments

Total Assets

AU$23.15 Million
≈ $16.38 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Paradigm Biopharmaceuticals Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Paradigm Biopharmaceuticals Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$71.83K 0.31%
Total Liquid Assets AU$71.83K 0.31%

Asset Resilience Insights

  • Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.31% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Abivax SA
PA:ABVX
Biotechnology 2.58%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Pulike Biological Engineering
SHG:603566
Biotechnology 17.82%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 14.00%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Upstream Bio, Inc.
NASDAQ:UPB
Biotechnology 64.70%

Annual Asset Resilience Ratio for Paradigm Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.00% AU$0.00
≈ $0.00
AU$24.57 Million
≈ $17.39 Million
--
2024-06-30 0.17% AU$46.20K
≈ $32.69K
AU$27.39 Million
≈ $19.38 Million
+0.10pp
2023-06-30 0.07% AU$46.20K
≈ $32.69K
AU$67.07 Million
≈ $47.46 Million
-0.02pp
2022-06-30 0.09% AU$46.20K
≈ $32.69K
AU$50.69 Million
≈ $35.87 Million
+0.04pp
2021-06-30 0.05% AU$46.20K
≈ $32.69K
AU$84.79 Million
≈ $60.00 Million
-0.61pp
2020-06-30 0.66% AU$746.20K
≈ $527.98K
AU$112.36 Million
≈ $79.50 Million
-6.94pp
2019-06-30 7.60% AU$6.50 Million
≈ $4.60 Million
AU$85.51 Million
≈ $60.50 Million
--
2017-06-30 0.00% AU$0.00
≈ $0.00
AU$14.35 Million
≈ $10.15 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$12.35 Million
≈ $8.74 Million
--
pp = percentage points

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology
Market Cap
$91.09 Million
AU$128.74 Million AUD
Market Cap Rank
#19628 Global
#642 in Australia
Share Price
AU$0.25
Change (1 day)
+0.00%
52-Week Range
AU$0.14 - AU$0.45
All Time High
AU$4.35
About

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more